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MaOBJECTIVES The aim of this study was to determine the incidence, predictors, and outcomes of recurrent stent
thrombosis (rST).
BACKGROUND Patients who had an initial stent thrombosis (ST) develop may be at high risk of rST.
METHODS We analyzed a multicenter California registry of angiographic deﬁnite ST at 5 academic hospitals from
2005 to 2013. A detailed review of the angiogram and procedure was performed of patients with and without rST.
RESULTS Among 221 patients with a median follow-up of 3.3 years, deﬁnite or probable rST developed in 29, including
19 with angiographic deﬁnite rST. The cumulative hazard ratio (HR) of deﬁnite or probable rST was 16% at 1 year and 24%
at 5 years, whereas the cumulative HR of angiographic deﬁnite rST was 11% at 1 year and 20% at 5 years. Despite similar
angiographic results, patients who had rST develop had signiﬁcantly greater peak creatine kinase at the time of initial ST
(mean, 2,655 mg/dl vs. 1,654 mg/dl; p ¼ 0.05) than those without rST. The 3-year rate of major adverse cardiovascular
events was 50% for patients with rST compared with 22% for patients with a single ST (p ¼ 0.01). After multivariable
adjustment, independent predictors of deﬁnite/probable rST were age (HR: 1.4; 95 conﬁdence interval [CI]: 1.1 to 1.8 per
10 years), bifurcation ST (HR: 4.4; 95% CI: 1.8 to 10.9), and proximal vessel diameter (HR: 1.8; 95% CI: 1.1 to 3.2 per
millimeter).
CONCLUSIONS rST represents an important cause of long-term morbidity and mortality after an initial ST. Bifurcation
ST and a larger proximal reference vessel diameter are independently associated with an increased risk of rST. (J Am Coll
Cardiol Intv 2014;7:1105–13) © 2014 by the American College of Cardiology Foundation.S tent thrombosis (ST) is a rare complication ofcoronary intervention with a high morbidityand mortality. First-time ST has an in-hospital
mortality rate of 5% to 10% and a 30-day mortalitym the *Department of Medicine, Division of Cardiology, University of C
dicine, Division of Cardiovascular Medicine, University of California-D
tional Heart Centre, Singapore; xDepartment of Medicine, Division of C
ssachusetts; kDepartment of Medicine, Division of Cardiovascular Medi
lifornia; {Department of Medicine, Division of Cardiology, University of Ca
#Department of Medicine, Veterans Affairs Medical Center, San Francis
bott Vascular; and receives research funding from Medtronic. Dr. Patel is
d is a consultant for Access Closure. Dr. Lim is a consultant for Volcano. Dr
entiﬁc. Dr. Rogers is a consultant for Volcano, Medtronic, and Boston Sc
dtronic and Eli Lilly; is a consultant for Eli Lilly; and has received resear
cumetrics, Cordis, and Sanoﬁ-Aventis. Dr. Shunk receives institutiona
raRedx, and Siemens Medical Systems; and is a consultant for TransAorti
ve no relationships relevant to the contents of this paper to disclose.
nuscript received February 13, 2014; revised manuscript received April 27rate of 10% to 25% (1–6). Among patients who survive
the initial episode of ST, recurrent ST (rST) is a
not uncommon cause of continued adverse cardio-
vascular events.olorado-Denver, Denver, Colorado; yDepartment of
avis, Davis, California; zDepartment of Cardiology,
ardiology, Massachusetts General Hospital, Boston,
cine, University of California-San Diego, San Diego,
lifornia-San Francisco, San Francisco, California; and
co, California. Dr. Yeo is on the Speakers’ Bureau of
on the Advisory Board of The Medicines Company;
. Low is a consultant for Abbott Vascular and Boston
ientiﬁc. Dr. Mahmud is on the Speakers’ Bureau of
ch support from Boston Scientiﬁc, Abbott Vascular,
l research support from Abbott Vascular, Gilead,
c Medical. All other authors have reported that they
, 2014, accepted May 8, 2014.
ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
HR = hazard ratio
LAD = left anterior descending
artery
MACE = major adverse
cardiovascular event(s)
PCI = percutaneous coronary
intervention
rST = recurrent stent
thrombosis
ST = stent thrombosis
TIMI = Thrombolysis In
Myocardial Infarction
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1106Although there are many biological,
clinical, and angiographic features that
contribute to initial ST, there are limited data
on the incidence, clinical presentation, and
outcomes of rST (7). Previous studies have
reported incidence rates of rST of 10% to 20%
during long-term follow-up (1–5,8). Two
smaller studies with detailed angiographic
analysis have also reported predictors of rST,
including residual thrombus burden after the
ﬁrst ST event, a larger vessel diameter,
residual dissection, and the presence of un-
derlying malignancy (9,10). However, each of
these studies was limited by a small number
of events and differences in practice pat-terns. A larger, multicenter study may therefore
better reﬂect real-world outcomes of rST.SEE PAGE 1114In this study, we used a multicenter ST registry to
analyze the incidence and outcomes of subjects with
rST. We hypothesized that angiographic ﬁndings at
the time of treatment for ST would be associated with
subsequent risk of rST.
METHODS
The University of California ST registry comprises
all cases of angiographic deﬁnite ST at 5 academic
medical centers (University of California, Davis; Uni-
versity of California, San Diego; San Francisco Veter-
an’s Administration Hospital; San Francisco General
Hospital; and University of California, San Francisco
Mofﬁtt-Long Hospital) from 2005 to 2013. Cases were
identiﬁed using cardiac catheterization laboratory re-
cords and, from 2008 onward, prospective enrollment
of subjects. After identiﬁcation of a potential ST, each
case was reviewed for clinical and angiographic char-
acteristics by 2 interventional cardiologists using the
Academic Research Consortium criteria for deﬁnite ST
(11). Only cases of angiographic deﬁnite ST were
included in the registry. For this analysis, the ﬁrst
presentation of ST was used as the entry criteria.
Once identiﬁed, cases were reviewed for de-
mographic, procedural, angiographic, and in-hospital
outcomes (12). Brieﬂy, trained abstractors and physi-
cians reviewed each medical chart for details of pre-
sentation, medications before admission, medication
compliance, procedural details of coronary angiog-
raphy and intervention, and in-hospital outcomes
(death, stroke, or repeat myocardial infarction).
Discharge medications were assessed for all surviving
patients. ST was deﬁned as occurring early if the
event occurred #30 days after the indexpercutaneous coronary intervention (PCI), late if it
occurred >30 days and <1 year after the index PCI,
and very late if it occurred $1 year after index PCI as
according to the Academic Research Consortium
criteria (11). Long-term mortality was assessed using
hospital records, patient follow-up, and the Social
Security Death Index. Patients who died within 30
days after initial ST without a deﬁnite etiology were
categorized as having probable rST, whereas patients
who presented with recurrent acute coronary syn-
drome and angiographic evidence of thrombus in the
same stent were categorized as have deﬁnite rST.
These deﬁnitions were on the basis of extension of
the Academic Research Consortium criteria to recur-
rent events of ST.
Angiographic analysis was performed by 2 inter-
ventional cardiologists blinded to outcomes. Quanti-
tative coronary analysis was performed using Xcelera
software (Philips Healthcare, Best, the Netherlands).
Thrombus grading was angiographically scored into
5 grades: 0 if there was no apparent thrombus; 1 if
possible thrombus was seen; 2 if deﬁnite thrombus
was one-half or less of the vessel diameter; 3 if deﬁ-
nite thrombus was more than one-half but <2 vessel
diameters; 4 if deﬁnite thrombus was $2 vessel di-
ameters; and 5 if there was complete vessel occlusion
from thrombus (13). All patients in the study had
grade 2 or higher thrombus to meet the deﬁnition of
deﬁnite ST. In cases in which there was complete
stent occlusion by thrombus, thrombus grading was
also recorded after initial lesion crossing with a wire
but before balloon inﬂation. Myocardial perfusion
was scored before and after intervention from 0 to 3,
as previously described (14). Corrected Thrombolysis
In Myocardial Infarction (TIMI) frame counts were also
scored for each infarct-related artery (15). A stent was
deﬁned as occurring at a bifurcation if the main vessel
stent crossed a side branch $2.0 mm in diameter
(provisional single stent), or if there were 2 stents
present, with 1 originating in a main vessel and the
second in a side branch (2-stent bifurcation). SYNTAX
(Synergy Between PCI With Taxus and Cardiac Surgery
Study) and residual SYNTAX scores were calculated as
previously described (16). All angiograms were also
scored for lesion calciﬁcation, lesion severity, moder-
ate/severe tortuosity, aneurysm, ectasia, and ulcera-
tion. A previously published risk scoring system for the
prediction of ST after initial angioplasty was also
calculated for patients with and without rST (17).
The primary outcome of the study was deﬁnite/
probable rST. Secondary endpoints included angio-
graphic deﬁnite rST, mortality, and major adverse
cardiovascular events (MACE), deﬁned as death,
myocardial infarction, or stroke.
TABLE 1 Demographic Characteristics
Deﬁnite or Probable
Recurrent ST
(n ¼ 29)
No Recurrent ST
(n ¼ 192) p Value
Age, yrs 64 (54–77) 61 (54–68) 0.09
Male 22 (76) 168 (88) 0.09
Previous CABG 4 (14) 25 (13) 0.9
Diabetes 13 (45) 73 (38) 0.5
Hypertension 16 (55) 152 (79) 0.005
Previous MI 20 (69) 140 (73) 0.7
Chronic kidney disease 4 (14) 29 (15) 0.9
Creatinine clearance 83 (61–105) 88 (62–112) 0.3
Previous malignancy 2 (7) 14 (7) 0.9
Ejection fraction, % 45 (35–50) 46 (40–55) 0.1
Current smoker 11 (38) 53 (28) 0.3
Taking aspirin 22 (76) 145 (76) 0.9
Taking thienopyridine 15 (52) 90 (47) 0.6
Dual-antiplatelet therapy 14 (48) 83 (43) 0.6
No current antiplatelet therapy 6 (21) 40 (21) 0.9
Taking a statin 23 (77) 142 (74) 0.5
Insured 21 (73) 142 (74) 0.9
Medication noncompliance 6 (21) 34 (18) 0.7
Presentation of ST 0.9
STEMI 20 (68) 127 (66)
NSTEMI 7 (24) 48 (25)
Unstable angina 2 (7) 17 (9)
ST timing 0.9
Early 10 (34) 59 (32)
Late 5 (17) 28 (16)
Very late 14 (48) 94 (52)
Intraprocedural ST 0 (0) 2 (1) 0.9
Type of previous stent 0.6
First-generation DES 16 (55) 88 (46)
Second-generation DES 3 (10) 16 (8)
BMS 4 (14) 47 (24)
Unknown 6 (21) 41 (21)
Cardiogenic shock 8 (29) 38 (20) 0.2
Intubation 5 (17) 18 (9) 0.2
CPR 3 (10) 9 (5) 0.2
Values are n (range) or n (%).
BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass grafting; CPR ¼ cardiopulmonary resuscitation;
DES ¼ drug-eluting stent(s); MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial
infarction; ST ¼ stent thrombosis; STEMI ¼ ST-segment elevation myocardial infarction.
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1107Values of mean  SD were used to describe nor-
mally distributed continuous data, whereas median
values with interquartile ranges were used to describe
non-normally distributed continuous variables. Nu-
merical values (percents) were used for categorical
variables. Continuous variables were compared using
the Wilcoxon rank sum test if non-normally distrib-
uted or t test if normally distributed. Categorical
values were compared by the chi-square test. The
cumulative hazard of rST was plotted as a function of
time. rST was treated as a time-varying variable in a
Cox proportional model to quantify the unadjusted
association between rST, MACE, and overall mor-
tality. A second Cox proportional hazard model was
also developed to identify predictors of deﬁnite or
probable rST. This model included all predictors with
a univariate association of <0.1 (age, sex, history of
hypertension, ejection fraction, stent thrombosis at
a bifurcation, proximal vessel reference diameter,
distal vessel reference diameter, presence of severe
calciﬁcation, lesion severity, and use of an intra-aortic
balloon pump) followed by stepwise elimination of
nonsigniﬁcant predictors. Bootstrapping with 100
repetitions was used to generate conﬁdence intervals
and p values. The ﬁnal model included age, ST at a
bifurcation, and proximal vessel reference diameter
as multivariable predictors of rST. All analyses were
performed using Stata version 11.2 (StataCorp., Col-
lege Station, Texas). A p value <0.05 was considered
signiﬁcant.
RESULTS
Among 221 patients with a median follow-up of
3.3 years, deﬁnite or probable rST developed in 29,
whereas 19 presented with angiographic deﬁnite rST.
The baseline demographic characteristics of patients
with and without deﬁnite or probable rST are sum-
marized in Table 1. Patients who had rST develop
were on average older (median age, 64 vs. 61 years),
were more often female (24% vs. 12%), and were less
likely to have a history of hypertension (55% vs. 79%,
p ¼ 0.005), but had a similar prevalence of medical
therapy at the time of initial ST including aspirin,
clopidogrel, and dual-antiplatelet therapy (48% vs.
43%, p ¼ 0.6). Twenty-one percent of patients were
not taking any antiplatelet therapy at the time of
presentation with initial ST. Among patients who had
interrupted antiplatelet therapy, 81% had stopped
aspirin for >1 week, and 82% had stopped taking
thienopyridine for >1 week. Reasons for dual-
antiplatelet interruption included physician decision
due to timing >1 year since the initial PCI in 56 pa-
tients, medication noncompliance in 40 patients,need for surgery in 9 patients, and bleeding in
2 patients. The presentation of the initial ST was
similar in those with and without subsequent rST,
with a similar prevalence of presentation with
ST-segment elevation myocardial infarction, throm-
bosis of a drug-eluting stent versus a bare metal stent,
and timing of the ST event.
The angiographic characteristics of patients are
summarized in Table 2. Half of the ST cases occurred
in the left anterior descending artery (LAD), and the
majority of cases had initial TIMI ﬂow grade <3,
thrombus grade of 4 or 5, and thrombus in the prox-
imal stent. Patients who had rST develop were more
TABLE 2 Angiographic Characteristics
Deﬁnite or Probable
Recurrent ST
(n ¼ 29)
No Recurrent ST
(n ¼ 192) p Value
Target vessel 0.8
LAD/diagonal 14 (48) 97 (51)
RCA 7 (24) 49 (26)
Circumﬂex 5 (17) 36 (19)
Bypass graft 3 (10) 10 (5)
Target vessel location 0.6
Ostial or proximal 14 (48) 108 (56)
Mid-distal 15 (52) 84 (44)
Angiographic collaterals 5 (17) 46 (24) 0.4
ST at bifurcation 10 (34) 22 (11) 0.001
Provisional stent* 7 (70) 15 (68) 0.8
2-stent* 3 (30) 7 (32) 0.8
LAD/diagonal* 7 (70) 11 (50) 0.3
Circumﬂex/OM* 3 (30) 8 (36) 0.8
RCA* 0 (0) 3 (14) 0.5
Side branch RVD* 2.3  0.7 2.0  0.4 0.006
Proximal vessel MLD, mm 3.4  0.7 3.0  0.6 0.007
Distal vessel MLD, mm 2.9  0.6 2.6  0.6 0.06
Initial TIMI ﬂow grade <3 26 (90) 174 (91) 0.9
Thrombus grade 0.5
1–3 5 (17) 24 (12)
4–5 24 (83) 168 (88)
Thrombus location in stent 0.4
Proximal 18 (62) 136 (71)
Mid-distal 11 (38) 56 (29)
SYNTAX score 22.5  12.8 20.7  11.1 0.4
Residual SYNTAX score 6.3  8.1 6.1  7.6 0.9
Severe calciﬁcation 5 (17) 14 (7) 0.08
Ostial lesion 3 (10) 15 (8) 0.6
Lesion severity
B1 7 (24) 21 (11) 0.05
B2 18 (62) 144 (75) 0.1
C 4 (14) 25 (13) 0.9
Moderate/severe tortuosity 2 (7) 27 (14) 0.3
No. with 2-vessel CAD 16 (55) 83 (43) 0.4
No. with 3-vessel CAD 3 (10) 27 (14) 0.8
CTO of nonculprit vessel 4 (14) 38 (20) 0.4
Ulceration 0 (0) 5 (3) 0.4
Aneurysm 0 (0) 1 (0.5) 0.7
Ectasia 2 (7) 18 (9) 0.7
ST risk score 3.9  0.6 3.8  0.7 0.3
Values are n (%) or mean  SD. *Provisional versus 2-stent, involved vessel, and side branch reference vessel
diameter are provided for patients with stent thrombosis at a coronary bifurcation (n ¼ 10 for recurrent stent
thrombosis and n ¼ 22 for no recurrent stent thrombosis).
CAD ¼ coronary artery disease; CTO ¼ chronic total occlusion; LAD ¼ left anterior descending artery; MLD ¼
minimal lumen diameter; OM ¼ obtuse marginal; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter;
ST ¼ stent thrombosis; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1108likely to have their initial ST at a coronary bifurcation
(34% vs. 11%, p ¼ 0.001) and had a larger proximal
reference vessel diameter by quantitative coronary
angiography (mean, 3.4  0.7 mm vs. 3.0  0.6 mm,
p ¼ 0.007). Among patients with ST at a bifurcation,
the majority of patients (69%) had been treated witha provisional single-stent strategy. Patients with
bifurcation ST who had rST develop had signiﬁcantly
larger side-branch vessel diameter compared with
patients without rST (2.3  0.7 mm vs. 2.0  0.4 mm,
p ¼ 0.006). There were no signiﬁcant differences be-
tween groups in target vessel location (ostial/proximal
vs. mid/distal), prevalence of an LAD versus non-LAD
target vessel (48% vs. 51%, p ¼ 0.8), baseline SYNTAX
score (22.5  12.8 vs. 20.7  11.1, p ¼ 0.4), or residual
SYNTAX score (6.3  8.1 vs. 6.1  7.6, p ¼ 0.9).
Table 3 summarizes the intraprocedural character-
istics and outcomes of the initial ST. The majority of
patients were treated with heparin, a glycoprotein
IIb/IIIa inhibitor, and implantation of a new drug-
eluting stent. The use of aspiration thrombectomy
was similar between groups (69% vs. 56%, p ¼ 0.2), as
well as the use of intravascular ultrasound (28% vs.
27%, p ¼ 0.9). Post-procedure TIMI ﬂow grade 3 was
achieved in 93% of patients who had rST subse-
quently develop and 90% of patients where rST did
not (p ¼ 0.5). There was also no difference between
groups in ﬁnal myocardial blush score or corrected
TIMI frame count, suggesting that both groups had
similar epicardial ﬂow and myocardial perfusion at
the conclusion of the procedure.
Despite similar angiographic results, patients who
had rST subsequently develop had signiﬁcantly
greater peak creatine kinase at the time of initial ST
(mean, 2,655  2,305 mg/dl vs. 1,654  1,786 mg/dl,
p ¼ 0.05) than those without rST, suggesting a greater
infarct size among those who had rST develop. The
ejection fraction at the time of hospitalization did not
differ signiﬁcantly between groups (43  12% vs. 47 
12%, p ¼ 0.1). In-hospital mortality was 5% overall
with the presentation of the initial ST. Among
patients who survived, medical therapy at discharge
included dual-antiplatelet therapy in all patients.
Prasugrel was prescribed in 11 cases, whereas the
remaining patients were prescribed clopidogrel
75 mg/day.
After accounting for censoring, the cumulative
hazard ratio (HR) of the development of deﬁnite or
probable rST was 16% (95% conﬁdence interval [CI]:
4% to 20%) at 1 year and 24% (95% CI: 16% to 36%) at
5 years of follow-up (Figure 1). The cumulative hazard
ratio of angiographic deﬁnite rST was 11% (95% CI: 7%
to 18%) at 1 year and 20% (95% CI: 11% to 33%) at
5 years (Figure 2). The median time to recurrent def-
inite/probable rST was 1.3 months (interquartile
range, 0.1 to 4.2 months), whereas the median time to
angiographic deﬁnite rST was 3.3 months (inter-
quartile range: 1.3 to 10.1 months).
The characteristics of the 19 patients who pre-
sented with angiographic deﬁnite rST are summarized
FIGURE 1 Incidence of Deﬁnite or Probable Recurrent
Stent Thrombosis
By 5 years of follow-up, the incidence of deﬁnite or probable
recurrent stent thrombosis (ST) was 24% (95% CI: 16% to 36%).
TABLE 3 Procedural Characteristics
Deﬁnite or Probable
Recurrent ST
(n ¼ 29)
No Recurrent ST
(n ¼ 192) p Value
PTCA without stent 9 (31) 71 (37) 0.5
Stent placement 0.3
BMS 6 (33) 25 (24)
First-generation DES 8 (44) 52 (49)
Second-generation DES 4 (22) 29 (20)
Heparin 21 (72) 144 (75) 0.7
Bivalirudin 6 (20) 41 (22) 0.9
Thrombectomy 20 (69) 108 (56) 0.2
Intravascular ultrasound 8 (28) 51 (27) 0.9
Intra-aortic balloon pump 8 (28) 28 (15) 0.08
Glycoprotein IIb/IIIa inhibitor 20 (69) 145 (76) 0.4
Post-procedure TIMI ﬂow 3 27 (93) 172 (90) 0.5
Final myocardial blush 0.9
0–2 19 (66) 139 (72)
3 10 (34) 53 (28)
Final cTFC 26  21 30  25 0.4
Residual dissection 0 0 1.0
Residual thrombus 2 (7) 20 (10) 0.8
Procedure success 28 (97) 172 (90) 0.2
Values are n (%) or mean  SD.
PTCA ¼ percutaneous transluminal coronary angioplasty; BMS ¼ bare metal stent; cTFC ¼
corrected TIMI frame count; other abbreviations as in Tables 1 and 2.
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1109in Table 4. Seven patients (37%) were noncompliant
with prescribed antiplatelet therapy at the time of
presentation with rST compared with 18% among
patients in whom rST did not develop. Six rSTs
occurred within 1 month, whereas 5 rSTs occurred
>1 year after the initial ST. Ten patients were treated
with new stent implantation, 8 patients had aspiration
thrombectomy and plain old balloon angioplasty
without new stent implantation, and 1 patient was
referred for urgent coronary artery bypass graft pro-
cedure. Two patients died in-hospital of heart failure.
Both of the in-hospital deaths occurred in patients
with rST of an LAD/diagonal bifurcation that had been
treated with a dedicated 2-stent approach. Among the
17 patients who survived to hospital discharge, 5 were
switched to more intensive antiplatelet therapy with
ticagrelor or prasugrel. During 3-year follow up, the
rate of major adverse cardiovascular events (MACE)
was 50% for patients with rST compared with 22%
for patients with a single ST (p ¼ 0.01) (Figure 3). The
3-year mortality rate of rST was 30%. In a Cox pro-
portional hazards model using rST as a time-varying
covariate, presentation with rST was associated with
signiﬁcantly higher risk of MACE (hazard ratio [HR]:
2.2; 95% CI: 1.1 to 4.6), but not with overall mortality
(HR: 1.9; 95% CI: 0.8 to 4.8).
Predictors of rST were identiﬁed using a Cox
proportional hazards model. On univariate analysis,
the predictors of deﬁnite/probable rST included age
(HR: 1.4; 95% CI: 1.1 to 1.7 per 10 years), bifurcation
ST (HR: 3.6; 95% CI: 1.7 to 7.8), proximal vessel
diameter (HR: 2.1; 95% CI: 1.2 to 3.4 per millimeter),
and history of hypertension (HR: 0.33; 95% CI: 0.16
to 0.69). After multivariable adjustment, the inde-
pendent predictors of deﬁnite/probable rST were age
(HR: 1.4; 95% CI: 1.1 to 1.8 per 10 years), bifurcation
ST (HR: 4.4; 95% CI: 1.8 to 10.9), and proximal
vessel diameter (HR: 1.8; 95% CI: 1.1 to 3.2 per
millimeter). These same predictors were also sig-
niﬁcant with a similar magnitude when entered into
a model that included only patients with angio-
graphic deﬁnite rST.
DISCUSSION
In this study, we describe the incidence, predictors,
and outcomes of rST. There are 3 major ﬁndings.
1) During long-term follow-up, angiographic deﬁnite
rST occurred with a 5-year incidence of 20%, whereas
deﬁnite/probable rST occurred with a 5-year inci-
dence of 24%. 2) After multivariable adjustment,
ST at a coronary bifurcation and a larger proximal
vessel reference diameter of the infarct-related artery
remained independent predictors of rST. 3) Themortality and rate of MACE was higher for rST than
for a ﬁrst-time ST event.
Although the initial reports of ST reported in-
hospital and short-term mortality rates exceeding
30%, more recent reports have suggested that the
in-hospital mortality rate of patients presenting to
the catheterization lab with ST is 5% to 8%, with a
FIGURE 2 Incidence of Angiographic Deﬁnite Recurrent
Stent Thrombosis
By 5 years of follow-up, the incidence of deﬁnite recurrent stent
thrombosis (ST) was 20% (95% CI: 11% to 33%).
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compared with early ST (1,4). Because most patients
who present to the hospital with a ﬁrst-time ST sur-
vive the initial hospitalization, the long-term out-
comes and risk of recurrent events therefore become
increasingly important. With an estimated 5-year rST
rate of 20% to 24%, patients require close follow-up
and optimal secondary prevention after the initial ST.
Our ﬁnding that bifurcation ST and a larger prox-
imal reference vessel diameter were independent
predictors of rST may help provide additional risk
stratiﬁcation by identifying the patients at highest
risk of rST. We previously reported that ST at a cor-
onary bifurcation is associated with an increased risk
of both short- and long-term MACE (18). Two major
mechanisms likely account for an increased rate of
rST among patients with coronary bifurcation ST.
First, ST at a bifurcation is associated with a larger
infarct, with subsequent increased risk of congestive
heart failure and left ventricular remodeling, which
may lead to a higher risk of subsequent thrombosis
(19). This larger infarct size may also predispose to
greater microvascular injury and subsequent poor
stent outﬂow with a greater risk of rST. Second,
exposed stent struts and an altered neocarina may
provide a continued nidus for thrombosis (20).
Compared with bifurcation ST, the mechanisms
relating a larger proximal reference vessel diameter
to rST are uncertain. It is possible that a larger refer-
ence diameter is a proxy for greater thrombus burden
and stasis predisposing to thrombosis because larger
proximal reference vessel size in the infarct-related
artery has been associated with a greater risk ofdistal vessel embolization (21). Interestingly, one
other group who examined predictors of rST also
identiﬁed proximal vessel reference diameter as a
predictor of rST (9). This ﬁnding in 2 separate cohorts
suggests that proximal reference vessel diameter may
be an important predictor of rST in multiple real-
world populations. We also speculate that stent
underexpansion or malapposition may contribute to
subsequent adverse events. We previously reported
these ﬁndings on the basis of intravascular ultrasound
in patients with ST (22). Therefore, careful attention
to accurate vessel sizing and stent deployment may
help mitigate against recurrent adverse events. On the
basis of these ﬁndings, we therefore believe that
intravascular ultrasound use should be strongly
considered during the treatment of all initial STs.
Although this study identiﬁed important angio-
graphic predictors of rST, other demographic and
procedural factors apart from age were not signiﬁcant
predictors of rST. Small case series have identiﬁed a
number of possible contributors to rST, including
hypercoagulable states, increased platelet turnover,
and rheumatological diseases (23–26). Previous
studies have suggested that residual dissection and
residual thrombus are also both predictors of rST (10).
There were no cases of residual dissection; this may
be in part due to the relatively higher use of intra-
vascular ultrasound in our cohort, which can provide
important mechanistic insight into the etiology of ST
(22). We also had a low rate of residual thrombus
in our study, likely related to the increased use of
thrombectomy at the registry sites compared with
previous studies. Although deﬁnitive studies are
lacking, appropriate use of intravascular ultrasound
and aspiration thrombectomy during treatment of ST
may help provide an optimal angiographic result and
thereby minimize the contribution of residual
dissection or residual thrombus to the risk of recur-
rent ST (27,28). We also found that repeat stent
placement during treatment of initial ST was rela-
tively common, exceeding 50%. Because this was a
retrospective study, it is difﬁcult to identify the
reason why a new stent was implanted in each case.
Interestingly, implantation of a new stent was not
associated with a greater risk of rST, suggesting that
other demographic and angiographic factors are more
important contributors to the overall risk of rST.
Given the high rate of recurrent events and the
increased in-hospital mortality of rST, secondary
prevention measures after treatment of initial ST
remain paramount. Because this study was conducted
from 2005 to 2013, the majority of patients were dis-
charged on aspirin and clopidogrel after their initial
ST event. With the recent availability of more potent
TABLE 4 Presentation and Outcomes of Angiographic Deﬁnite Recurrent Stent Thrombosis
Patient #
Time
to rST
Antiplatelet at
Time of rST Compliance Vessel Bifurcation
Proximal
Vessel, mm Platelet Resist Type Stent EF, % In-Hospital Treatment and Outcome
1 <1 day Aspirin and
clopidogrel
Yes Circ/OM Yes 2.6 N/A DES 45 Repeat ST 8 h after original ST
treatment. Aspiration
thrombectomy and POBA,
started on prasugrel.
2 <1 day Aspirin and
clopidogrel
Yes RCA No 3.7 N/A DES 50 2 recurrent STs within 48 h.
IVUS showed residual
thrombus but no
underexpansion or
dissection, started
on prasugrel.
3 4 days Aspirin and
clopidogrel
Yes RCA No 3.7 N/A DES 40 Aspiration thrombectomy and
BMS. Prolonged hospitalization
(30 days) with CHF.
4 5 days Aspirin and
clopidogrel
Yes LAD/Diag Yes 3.3 Clopidogrel DES 25 Aspiration thrombectomy and
DES. IVUS revealed stent
underexpansion. Patient died
in hospital of heart failure.
5 1 month Aspirin and
clopidogrel
Yes SVG No 3.7 N/A BMS 50 New BMS.
6 1 month None No Left main No 2.8 N/A BMS 20 POBA, d/c on prasugrel after
prolonged hospitalization
with CHF.
7 2 months Aspirin No RCA No 4.0 Aspirin and
clopidogrel
BMS 45 Noncompliant with clopidogrel.
Aspiration thrombectomy
and BMS.
8 2 months Aspirin No LAD/Diag Yes 2.5 N/A DES 50 Noncompliant with clopidogrel.
POBA, started on ticagrelor.
9 2 months Aspirin and
clopidogrel
Yes RCA No 3.6 N/A BMS 25 Aspiration thrombectomy and
BMS. No underexpansion or
malapposition on IVUS.
10 3 months None No LAD/Diag Yes 2.8 N/A BMS 45 Noncompliant with aspirin and
clopidogrel. Treated
with DES.
11 5 months Aspirin and
clopidogrel
Yes LAD/Diag Yes 2.3 N/A DES 20 Aspiration thrombectomy and
BMS. Patient died in hospital
of heart failure.
12 5 months Aspirin and
clopidogrel
Yes LAD No 3.2 Clopidogrel DES 55 Referred for urgent CABG.
13 11 months Aspirin and
clopidogrel
Yes RCA No 3.1 N/A DES 45 POBA only. Started on prasugrel.
14 12 months Aspirin and
clopidogrel
Yes SVG No 2.7 N/A BMS 60 Aspiration thrombectomy and DES.
15 13 months None No LAD No 3.2 N/A BMS 55 Pt stopped ASA and clopidogrel
1 week earlier. Aspiration
thrombectomy and POBA.
16 21 months Aspirin and
clopidogrel
Yes LAD No 3.5 N/A DES 30 Aspiration thrombectomy and DES.
17 2 yrs None No RCA No 3.6 N/A DES 55 Aspiration thrombectomy and
POBA. Second rST occurred
1 yr later, and patient
switched to ticagrelor.
18 2.5 yrs Aspirin and
clopidogrel
Yes SVG No 2.9 N/A DES 65 POBA and DES.
19 4.5 yrs None No RCA No 2.9 N/A DES 45 POBA only.
CHF ¼ congestive heart failure; Circ ¼ circumﬂex; d/c ¼ discharged; EF ¼ ejection fraction; IVUS ¼ intravascular ultrasound; N/A ¼ not available; POBA ¼ plain old balloon angioplasty; Pt ¼ patient;
rST ¼ recurrent stent thrombosis; SVG ¼ saphenous vein graft; diag ¼ diagonal; other abbreviations as in Tables 1 and 2.
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1111antiplatelet agents including ticagrelor and prasugrel,
it has become frequent practice to prescribe 1 of these
2 agents (in addition to aspirin) after an initial ST.
This clinical approach is on the basis of extrapolation
from clinical trial data in de novo acute coronary
syndromes, in which both ticagrelor and prasugrelwere associated with lower rates of ST than clopi-
dogrel (29,30). Given the ﬁndings of our study, pa-
tients with bifurcation ST and/or a large reference
vessel diameter should especially be considered for
treatment with one of these agents after an initial ST.
Additional antithrombotic approaches could also be
FIGURE 3 Outcomes of First-Time Versus Recurrent
Stent Thrombosis
(A) The 3-year mortality rate of recurrent stent thrombosis (ST)
was 30% versus 17% for a ﬁrst-time ST without recurrence
(p ¼ 0.1). (B) The 3-year major adverse cardiovascular event
(MACE) rate was 50% versus 22% (p¼0.01). Mortality andMACE
rates are on the basis of Kaplan-Meier estimates.
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1112considered, including use of rivaroxaban to reduce
rates of recurrent ischemia, although the possible
increased risk of bleeding complications should be
strongly considered (31).
STUDY LIMITATIONS. Although this is the largest
reported angiographic study of rST, several limita-
tions should be considered. First, patients were not
routinely tested for resistance to aspirin or clopi-
dogrel. Recent case-control and cohort studies have
suggested that patients with ST have an increased
prevalence of aspirin and/or clopidogrel resistance
and that tailored therapy can overcome this resis-
tance when assessed by platelet functional assays
(32–35). However, the clinical utility of this approachremains uncertain because trials of increased or more
intensive antiplatelet dosing on the basis of platelet
function assays have failed to translate into reduced
clinical events in patients after stenting of de novo
coronary lesions (36,37). Second, the rates of dual-
antiplatelet therapy discontinuation after initial ST
were on the basis of follow-up chart data and may
not have reﬂected actual patient compliance with
medications. Third, the rates of possible ST could not
be accurately determined because a cause of death
could not be identiﬁed using the Social Security
Death Index in all patients during long-term follow-
up. We therefore limited our deﬁnition of rST to rates
of angiographic deﬁnite and probable rST. For pa-
tients with deﬁnite/probable rST with unexplained
death in the ﬁrst 30 days, it is possible that a fatal
arrhythmia and not rST accounted for mortality.
Fourth, we do not have data on timing from symp-
tom onset to presentation to the hospital, and it is
therefore possible that the higher mortality rate of
patients with rST is related to delayed presentation.
Fifth, the study period from 2005 to 2013 reﬂects
primarily a timeframe before frequent use of tica-
grelor and prasugrel. It is possible that rates of rST
will decrease with more potent antiplatelet use and
with newer generation drug-eluting stents (38–40).
Sixth, the low number of total events limits the
ability to perform extensive multivariable analysis. It
is possible that other predictors of rST could emerge
with a larger study size.
CONCLUSIONS
rST represents an important cause of long-term
morbidity and mortality after an initial ST event.
Bifurcation ST and a larger proximal reference vessel
diameter are independently associated with an
increased risk of rST. Given the high mortality of rST,
patients should be aggressively treated with an
intensive antiplatelet strategy after an initial ST.
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